ArticleAmino acids2018
Alamandine attenuates hypertension and cardiac hypertrophy in hypertensive rats.
Article in Amino acids, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.
- Association of LIPC -250G/A and -514C/T polymorphisms and hypertension: a systematic review and meta-analysis.Lipids in health and disease · 2018Pooled it
- Cardiac hypertrophy at the crossroads: Mechanistic insights and emerging multimodal therapeutic strategies.European journal of pharmacology · 2025Review
- Antihypertrophic effects of the seed ethanolic extract ofToxicology reports · 2025Article
- Angiotensin-(1-7) and Central Control of Cardiometabolic Outcomes: Implications for Obesity Hypertension.International journal of molecular sciences · 2024Review
- Interval training suppresses nod-like receptor protein 3 inflammasome activation to improve cardiac function in myocardial infarction rats by hindering the activation of the transforming growth factor-β1 pathway.Journal of cardiothoracic surgery · 2024Article
- Effects of alamandine on monocrotaline-induced pulmonary hypertension in rats.Iranian journal of basic medical sciences · 2024Article
- Nuclear import of Mas-related G protein-coupled receptor member D induces pathological cardiac remodeling.Cell communication and signaling : CCS · 2023Article
- An overview of alamadine/MrgD signaling and its role in cardiomyocytes.American journal of physiology. Cell physiology · 2023Review
- Counter-regulatory renin-angiotensin system in hypertension: Review and update in the era of COVID-19 pandemic.Biochemical pharmacology · 2023Review
- Alamandine alleviated heart failure and fibrosis in myocardial infarction mice.Biology direct · 2022Article
- Tumstatin (69-88) alleviates heart failure via attenuating oxidative stress in rats with myocardial infarction.Heliyon · 2022Article
- Downregulation of amphiregulin improves cardiac hypertrophy via attenuating oxidative stress and apoptosis.Biology direct · 2022Article
- Alamandine alleviates hypertension and renal damage via oxidative-stress attenuation in Dahl rats.Cell death discovery · 2022Article
- Angiotensin-(3-7) alleviates isoprenaline-induced cardiac remodeling via attenuating cAMP-PKA and PI3K/Akt signaling pathways.Amino acids · 2021Article
- Classical and Counter-Regulatory Renin-Angiotensin System: Potential Key Roles in COVID-19 Pathophysiology.CJC open · 2021Review
- Alarin alleviated cardiac fibrosis via attenuating oxidative stress in heart failure rats.Amino acids · 2021Article
- Tanshinone IIA attenuates heart failure via inhibiting oxidative stress in myocardial infarction rats.Molecular medicine reports · 2021Article
- Protective effect of alamandine on doxorubicin‑induced nephrotoxicity in rats.BMC pharmacology & toxicology · 2021Article
- MicroRNA-132 attenuated cardiac fibrosis in myocardial infarction-induced heart failure rats.Bioscience reports · 2020Article
- Alamandine enhances cardiomyocyte contractility in hypertensive rats through a nitric oxide-dependent activation of CaMKII.American journal of physiology. Cell physiology · 2020Article
Corrections and comments
- Retraction · 2025-03-25Concerns/Issues about Image · Duplication of/in Image · Euphemisms for Duplication · Objections by Author(s) · Unreliable Data · · See also: https://pubpeer.com/publications/73E4DCD4457A3B5C7691C4B697473A
- Retracted
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Oral administration of the peptide alamandine has antihypertensive and anti-fibrotic effects in rats. This work aimed to determine whether subcutaneous alamandine injection would attenuate hypertension and cardiac hypertrophy, and improve the function of a major target of hypertension-related damage, the left ventricle (LV), in spontaneously hypertensive rats (SHRs). This was examined in vivo in SHRs and normotensive rats subjected to 6-week subcutaneous infusion of alamandine or saline control, and in vitro in H9C2-derived and primary neonatal rat cardiomyocytes treated with angiotensin (Ang) II to model cardiac hypertrophy. Tail artery blood pressure measurement and transthoracic echocardiography showed that hypertension and impaired LV function in SHRs were ameliorated upon alamandine infusion. Alamandine administration also decreased the mass gains of heart and lung in SHRs, suppressed cardiomyocyte cross-sectional area expansion, and inhibited the mRNA levels of atrial natriuretic peptide and brain natriuretic peptide. The expression of alamandine receptor Mas-related G protein-coupled receptor, member D was increased in SHR hearts and in cardiomyocytes treated with Ang II. Alamandine inhibited the increases of protein kinase A (PKA) levels in the heart in SHRs and in cardiomyocytes treated with Ang II. In conclusion, the present study showed that alamandine administration attenuates hypertension, alleviates cardiac hypertrophy, and improves LV function. PKA signaling may be involved in the mechanisms underlying these effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.